34955-23-2

Upstream product

• 100-70-9 2-Cyanopyridine 
• 6610-29-3 4-methylthiosemicarbazide 
• 98-98-6 2-Picolinic acid 
• 34955-22-1 4-methyl-1-(pyridine-2-carbonyl)-thiosemicarbazide 
• 1452-63-7 picolinic acid hydrazide 

Relevant academic research and scientific papers

In situ generation of functionalized 1,2,4-triazole-5-thiones containing pyridine or pyrazine moieties and their coordination to HgII

The reaction of 2-cyanopyridine or 2-cyanopyrazine with N-methylthiosemicarbazide afforded (Z)-2-(amino(pyridin-2-yl)methylene)-N-methylhydrazinecarbothioamide (HPyAm4M) and (Z)-2-(amino(pyrazin-2-yl)methylene)-N-methylhydrazinecarbothioamide (HPzAm4M), respectively. Prolonged heating under reflux in methanol in the synthesis of these thiosemicarbazones led to the formation of 4-methyl-5-pyridin-2-yl-2,4-dihydro-[1,2,4]triazole-5-thione (HMPytat, 1) and 4-methyl-5-pyrazin-2-yl-2,4-dihydro-[1,2,4]triazole-5-thione (HMPztat, 2) by oxidative cyclization of the starting thiosemicarbazones. Reactions of thiosemicarbazones with mercury(II) salts gave new complexes of general formulae [Hg(tat)X] (3, 4) and [Hg(Htat)2X2] (5, 7, 9-11), along with [Hg3(HEPytat)2(EPytat)2Cl4]·3H2O (6) and [Hg(EPytat)(HEPytat)I]·H2O (8) (Htat = general 1,2,4,-triazole-5-thione). The complexes were isolated as solids and were characterized by elemental analysis, mass spectrometry and IR, 1H NMR and 13C NMR spectroscopy. Recrystallization of the complexes from DMSO gave the compounds [Hg(MPytat)2]n (3a), [Hg(HMPytat)2Br2]·H2O (4a), [{Hg(HEPytat)(μ2-NS-EPytat)Cl2}2Hg] (6a), [Hg(EPytat)2]n (6b), [Hg(MPztat)2]n (10a) and [Hg(EPztat)2]n (11a) (HEPytat = 4-ethyl-5-pyridin-2-yl-2,4-dihydro-[1,2,4]triazole-5-thione and HEPztat = 4-ethyl-5-pyrazin-2-yl-2,4-dihydro-[1,2,4]triazole-5-thione). These complexes were studied by single-crystal X-ray diffraction. The structural analysis revealed the versatility of heterocyclic functionalized 1,2,4-triazole-5-thiones to coordinate to mercury(II) in the thione and thiolate forms through the use of various donor atoms to give different and interesting crystalline packings. The supramolecular assemblies observed in the solid state were analysed. These elegant assemblies are formed by a combination of several noncovalent interactions, including intermolecular hydrogen-bonding supramolecular synthons and aromatic-aromatic interactions. The short Hg?Hg distance of 3.660 ? indicates the presence of a probable mercurophilic interaction in 6a.

A High-Throughput Glycosyltransferase Inhibition Assay for Identifying Molecules Targeting Fucosylation in Cancer Cell-Surface Modification

In cancers, increased fucosylation (attachment of fucose sugar residues) on cell-surface glycans, resulting from the abnormal upregulation of the expression of specific fucosyltransferase enzymes (FUTs), is one of the most important types of glycan modifications associated with malignancy. Fucosylated glycans on cell surfaces are involved in a multitude of cellular interactions and signal regulation in normal biological processes, as well as in disease. For example, sialyl LewisX is a fucosylated cell-surface glycan that is abnormally abundant in some cancers where it has been implicated in facilitating metastasis, allowing circulating tumor cells to bind to the epithelial tissue within blood vessels and invade into secondary sites by taking advantage of glycan-mediated interactions. To identify inhibitors of FUT enzymes as potential cancer therapeutics, we have developed a novel high-throughput assay that makes use of a fluorogenically labeled oligosaccharide as a probe of fucosylation. This probe, which consists of a 4-methylumbelliferyl glycoside, is recognized and hydrolyzed by specific glycoside hydrolase enzymes to release fluorescent 4-methylumbelliferone, yet when the probe is fucosylated prior to treatment with the glycoside hydrolases, hydrolysis does not occur and no fluorescent signal is produced. We have demonstrated that this assay can be used to measure the inhibition of FUT enzymes by small molecules, because blocking fucosylation will allow glycosidase-catalyzed hydrolysis of the labeled oligosaccharide to produce a fluorescent signal. Employing this assay, we have screened a focused library of small molecules for inhibitors of a human FUT enzyme involved in the synthesis of sialyl LewisX and demonstrated that our approach can be used to identify potent FUT inhibitors from compound libraries in microtiter plate format.

Design, synthesis and antibacterial evaluation of 1-[(1R,2S)-2-Fluorocyclopropyl] Ciprofloxacin-(4-Methyl-3-Aryl)-1,2,4-Triazole-5(4H)-Thione Hybrids

Fourteen novel 1-[(1R,2S)-2-Fluorocyclopropyl]ciprofloxac in-(4-methyl-3-aryl)-1,2,4-triazole-5(4H)-thione hybrids 6a-n were designed, synthesized and assessed for their in vitro antibacterial activities against representative Gram-positive and Gram-negat

SELECTIVE HDAC6 INHIBITORS

The present invention relates to novel benzohydroxamic compounds of formula (I) and (II) and pharmaceutically acceptable salts, isomers and prodrugs thereof, exhibiting a high selective inhibitory activity against histone deacetylase 6 (HDAC6) enzyme.

DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY

The disclosure provides compounds having formula (I), wherein the substituents are as defined herein. The compounds are useful for modulating the dopamine D3 receptor and for treating conditions associated therewith, such as addictions, drug dependency, and psychiatric conditions.

DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS

The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.

1,2,4-Triazolyl octahydropyrrolo[2,3-b]pyrroles: A new series of potent and selective dopamine D3 receptor antagonists

A novel series of 1,2,4-triazolyl octahydropyrrolo[2,3-b]pyrroles showing high affinity and selectivity at the DA D3 receptor is reported here. Compounds endowed with high selectivity over the hERG channel were identified and their pharmacokinetic properties thoroughly analyzed. A few derivatives with appropriate developability characteristics were selected for further studies and progression along the screening cascade. In particular, derivative 60a, (DA D3 pKi = 8.4, DA D2 pKi = 6.0 and hERG fpKi = 5.2) showed a balanced profile and further refinements are in progress around this molecule.

1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists

A novel series of 1,2,4-triazolyl 5-azaspiro[2.4]heptanes with high affinity and selectivity at the dopamine (DA) D3 receptor (D3R) is described. Some of these compounds also have high selectivity over the hERG channel and were characterized with respect to their pharmacokinetic properties both in vitro and in vivo during lead identification and early lead optimization phases. A few derivatives with overall favorable developability characteristics were selected for further late lead optimization studies.

TRIAZOLE COMPOUNDS AND THE THERAPEUTIC USE THEREOF

The invention relates to triazole compounds of general formula (I), wherein A, B, R1, R2, R3 and R4 have the meaning cited in claim 1. The invention also relates to a pharmaceutical agent containing at least one compound of general formula (I) in addition to the use of the compound (I) for producing a pharmaceutical agent for treating illnesses, responding to the effects of dopamine-D3-receptor antagonists or dopamine-D3-receptor agonists, especially for treating disorders in the central nervous system.

NEW COMPOUNDS

The present invention relates to new compounds of formula I, (I) a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.